Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Anika Therapeutics Inc. - Common Stock (NQ:ANIK)

8.360 -0.230 (-2.68%)
Streaming Delayed Price Updated: 3:09 PM EDT, Aug 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Anika Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 Next >
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anika Therapeutics, Inc. - ANIK
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anika Therapeutics, Inc. - ANIK
From Pomerantz LLP
Via GlobeNewswire
ANIKA (ANIK) ALERT: Bragar Eagel & Squire, P.C. Continues Investigating Anika Therapeutics, Inc. on Behalf of Anika Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Earnings Scheduled For July 30, 2025
 
Via Benzinga
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Anika Therapeutics, Inc. - ANIK
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anika Therapeutics, Inc. - ANIK
From Pomerantz LLP
Via GlobeNewswire
ANIKA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Anika Therapeutics, Inc. on Behalf of Anika Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Kirby McInerney LLP Announces Investigation Against Anika Therapeutics, Inc. (ANIK) on Behalf of Investors
From Kirby McInerney LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anika Therapeutics, Inc. - ANIK
From Pomerantz LLP
Via GlobeNewswire
Anika (ANIK) Q2 Revenue Beats by 4%
Via The Motley Fool
Topics Economy
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Via Benzinga
ANIKA THERAPEUTICS INC (NASDAQ:ANIK) Reports Mixed Q2 2025 Results with Revenue Beat but EPS Miss, Shares Drop 9% in Pre-Market
Anika Therapeutics reported mixed Q2 2025 results, with revenue beating estimates but EPS missing. Shares fell 9% amid Hyalofast trial concerns despite strong regenerative solutions growth. 
Via Chartmill
Anika Reports Topline Results from U.S. Pivotal FastTRACK Phase III Study for Hyalofast® Cartilage Repair Scaffold and Provides Program Update
From Anika Therapeutics Inc.
Via GlobeNewswire
Anika to Issue Second Quarter 2025 Financial Results on Wednesday, July 30, 2025
From Anika Therapeutics Inc.
Via GlobeNewswire
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Anika Therapeutics Inc.
Via GlobeNewswire
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Anika Therapeutics Inc.
Via GlobeNewswire
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Anika Therapeutics Inc.
Via GlobeNewswire
Earnings Scheduled For May 9, 2025
 
Via Benzinga
A Glimpse of Anika Therapeutics's Earnings Potential
 
Via Benzinga
Anika to Participate in the Sidoti Virtual Investor Conference
From Anika Therapeutics Inc.
Via GlobeNewswire
Anika to Issue First Quarter 2025 Financial Results on Friday, May 9, 2025
From Anika Therapeutics Inc.
Via GlobeNewswire
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Anika Therapeutics Inc.
Via GlobeNewswire
Microsoft To Rally More Than 17%? Here Are 10 Top Analyst Forecasts For Thursday
 
Via Benzinga
US Stocks Likely To Open Lower After A Brief Respite: 'Add Exposure To Equities' Amid Pullback, Says Expert
U.S. stock futures fell again on Thursday after a brief respite on Wednesday, following a softer-than-expected inflation print. 
Via Benzinga
Topics Economy
Why Intel Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Earnings Scheduled For March 12, 2025
 
Via Benzinga
Anika Completes Divestiture of Parcus Medical
Execution of Previously Announced Plan Sharpens Focus on Hyaluronic Acid-Driven OA Pain Management and High Growth Regenerative Solutions Portfolio 
From Anika Therapeutics Inc.
Via GlobeNewswire
Anika to Issue Fourth Quarter and Year-End 2024 Financial Results on Wednesday, March 12, 2025
From Anika Therapeutics Inc.
Via GlobeNewswire
Anika To Present at the Canaccord Genuity 2025 Musculoskeletal Conference
From Anika Therapeutics Inc.
Via GlobeNewswire
Anika To Participate in 43rd Annual J.P. Morgan Healthcare Conference
From Anika Therapeutics Inc.
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.